EFFECT OF STREPTOMYCIN ON BLOOD CLOTTING TIME AND PROTHROMBIN TIME IN MAN

1949 ◽  
Vol 217 (4) ◽  
pp. 421-426 ◽  
Author(s):  
Leo Elson
Keyword(s):  
Prothrombin Time ◽  
Blood Clotting ◽  
Clotting Time ◽  
Blood Clotting Time

scholarly journals The Effect of Wheatgrass Lyophilizate on Blood Clotting Time in Rats

2021 ◽  
Vol 89 (3) ◽  
pp. 39
Author(s):  
István Takács ◽  
Melinda Urkon ◽  
Tivadar Kiss ◽  
Edina Horváth ◽  
Eszter Laczkó-Zöld ◽  
...  
Keyword(s):  
Prothrombin Time ◽  
Blood Clotting ◽  
Clinical Evidence ◽  
Anticoagulant Activity ◽  
Oral Anticoagulants ◽  
Animal Experiments ◽  
Potential Interaction ◽  
Flavonoid Content ◽  
Clotting Time ◽  
Blood Clotting Time

Wheatgrass is widely used in the alternative medicine, however, there is a lack of clinical evidence to support its efficacy. Although based on its chemical composition, data from animal experiments and clinical trials, the use of juice and extracts of Triticum shoots seems to be safe, clinical reports point out its potential interaction with oral anticoagulants. The aim of our study was to assess the interaction of wheatgrass with warfarin in rats and to assess its flavonoid content. Three groups of animals were treated orally with wheatgrass, warfarin, or the combination of wheatgrass and warfarin for five days. Clotting assays were performed using platelet-poor plasma. Prothrombin time was determined by optical and mechanical coagulometers. Flavonoid content of wheatgrass was measured by HPLC. The effect of wheatgrass on prothrombin time was not confirmed. Co-administration of wheatgrass and warfarin did not result in diminished anticoagulant activity. Low amount of flavonoids was detected in wheatgrass juice, the total flavonoid content was 0.467 mg/100 g lyophilized juice powder. The previously reported rutin, quercetin and apigenin was not detected by us. Our results do not confirm the probability of interaction of wheatgrass with oral anticoagulants. However, the low flavonoid content of wheatgrass does not support its use as an antioxidant.

Effective Reversal of Edoxaban-associated Bleeding with Four-factor Prothrombin Complex Concentrate in a Rabbit Model of Acute Hemorrhage

2015 ◽  
Vol 122 (2) ◽  
pp. 387-398 ◽  
Author(s):  
Eva Herzog ◽  
Franz Kaspereit ◽  
Wilfried Krege ◽  
Baerbel Doerr ◽  
Jochen Mueller-Cohrs ◽  
...  
Keyword(s):  
Blood Loss ◽  
Prothrombin Time ◽  
Whole Blood ◽  
Thrombin Generation ◽  
Blood Clotting ◽  
Prothrombin Complex Concentrate ◽  
Rabbit Model ◽  
Clotting Time ◽  
Blood Clotting Time

Abstract Background: Edoxaban is an oral, selective direct factor Xa inhibitor approved in Japan for venous thromboembolism prevention after orthopedic surgery. Data are lacking regarding reversal strategies for edoxaban; this study assessed whether four-factor prothrombin complex concentrate (Beriplex®/Kcentra®; CSL Behring GmbH, Marburg, Germany) can effectively reverse its effects on hemostasis using a previously described rabbit model. Methods: The study comprised assessments of thrombin generation in vitro, pharmacokinetic parameters, and edoxaban reversal in vivo. In a blinded in vivo stage, a standardized kidney incision was performed in animals (n = 11 per group) randomized to receive vehicle + saline, edoxaban (1,200 μg/kg) + saline, or edoxaban (1,200 μg/kg) + four-factor prothrombin complex concentrate (50 IU/kg). Animals were monitored for treatment impact on hemostasis and coagulation parameters. Data are median (range). Statistical tests were adjusted for multiple testing. Results: Edoxaban administration increased blood loss (30 [2 to 44] ml) and time to hemostasis (23 [8.5 to 30.0] min) compared with the control group (3 [1 to 8] ml and 3 [2.0 to 5.0] min, respectively). Biomarkers of coagulation (prothrombin time, activated partial thromboplastin time, whole blood clotting time) and thrombin generation parameters (e.g., peak thrombin, endogenous thrombin potential, lag time) were also affected by edoxaban. Administration of four-factor prothrombin complex concentrate significantly reduced time to hemostasis (to 8 [6.5 to 14.0] min, observed P < 0.0001) and total blood loss (to 9 [4 to 22] ml, observed P = 0.0050) compared with the edoxaban + saline group. Of the biomarkers tested, prothrombin time, whole blood clotting time, and endogenous thrombin potential correlated best with clinical parameters. Conclusion: In a rabbit model of hemostasis, four-factor prothrombin complex concentrate administration significantly decreased edoxaban-associated hemorrhage.

Addition of Prothrombin to Blood from Dogs Receiving Dicumarol

1965 ◽  
Vol 13 (01) ◽  
pp. 187-193 ◽  
Author(s):  
Heinz Schröer ◽  
D. L Heene ◽  
W. H Seegers
Keyword(s):  
Prothrombin Time ◽  
Whole Blood ◽  
Glass Surface ◽  
Blood Clotting ◽  
Factor Ix ◽  
Clotting Time ◽  
Dog Plasma ◽  
Glass Tubes ◽  
Dog Blood ◽  
Blood Clotting Time

SummaryThe prothrombin concentration of dog plasma was lowered by giving large doses of Dicumarol. The dog blood was then mixed with progressive increments of purified bovine prothrombin. When the concentration of prothrombin was equivalent to normal the whole blood clotting time and the prothrombin time were normal. The purified prothrombin supplied all that was essential and did not add detectable amounts of extraneous pro coagulant power. The residual prothrombin in the serum was generally higher when clotting occurred in silicone lined test tubes than in glass. In silicone tubes very little hemophilia B (factor IX, autoprothrombin II) activity developed. This activity was found in the glass tubes in a concentration proportional to the original prothrombin added. The transformation of prothrombin to autoprothrombin II occurred in plasma when there was a glass surface.

scholarly journals Evolving Paradigm of Prothrombin Time Diagnostics with Its Growing Clinical Relevance towards Cardio-Compromised and COVID-19 Affected Population

Sensors ◽  
2021 ◽  
Vol 21 (8) ◽  
pp. 2636
Author(s):  
Anubhuti Saha ◽  
Ashutosh Bajpai ◽  
Vinay Krishna ◽  
Shantanu Bhattacharya
Keyword(s):  
Prothrombin Time ◽  
Clinical Relevance ◽  
Blood Clotting ◽  
Point Of Care ◽  
Anticoagulation Therapy ◽  
Clotting Time ◽  
Efficient Point ◽  
Hemorrhagic Complications ◽  
Coagulation Dynamics ◽  
Blood Clotting Time

Prothrombin time (PT) is a significant coagulation (hemostasis) biomarker used to diagnose several thromboembolic and hemorrhagic complications based on its direct correlation with the physiological blood clotting time. Among the entire set of PT dependents, candidates with cardiovascular ailments are the major set of the population requiring lifelong anticoagulation therapy and supervised PT administration. Additionally, the increasing incidence of COVID affected by complications in coagulation dynamics has been strikingly evident. Prolonged PT along with sepsis-induced coagulopathy (SIC score > 3) has been found to be very common in critical COVID or CAC-affected cases. Considering the growing significance of an efficient point-of-care PT assaying platform to counter the increasing fatalities associated with cardio-compromised and coagulation aberrations propping up from CAC cases, the following review discusses the evolution of lab-based PT to point of care (PoC) PT assays. Recent advances in the field of PoC PT devices utilizing optics, acoustics, and mechanical and electrochemical methods in microsensors to detect blood coagulation are further elaborated. Thus, the following review holistically aims to motivate the future PT assay designers/researchers by detailing the relevance of PT and associated protocols for cardio compromised and COVID affected along with the intricacies of previously engineered PoC PT diagnostics.

The Blood-Clotting Time in Spent Silver Salmon, Oncorhynchus kisutch (Walbaum)

Copeia ◽  
1950 ◽  
Vol 1950 (2) ◽  
pp. 150 ◽  
Author(s):  
Max Katz ◽  
Morris Southward
Keyword(s):  
Blood Clotting ◽  
Oncorhynchus Kisutch ◽  
Clotting Time ◽  
Blood Clotting Time

Autoprothrombin II of human origin

1961 ◽  
Vol 201 (4) ◽  
pp. 660-662 ◽  
Author(s):  
Orhan N. Ulutin ◽  
J. Frederic Johnson ◽  
Walter H. Seegers
Keyword(s):  
Whole Blood ◽  
Blood Clotting ◽  
Human Origin ◽  
Clotting Time ◽  
Generation Test ◽  
Blood Clotting Time

Autoprothrombin II activity develops when prothrombin preparations of human origin are activated with purified thrombin at pH 8.2. Early during the activation an inhibitor seems to form. Concentrates of the autoprothrombin II can replace serum in the thromboplastin generation test provided platelets are used in the test, but not if a soy bean phosphatide is used. Dogs were given Coumadin in doses that lowered their own autoprothrombin concentration practically to zero. Then while continuing with use of the drug some purified autoprothrombin II was infused intravenously. This was tolerated very well. The autoprothrombin II concentration stayed at normal for 7 hr. In 24 hr none remained. The infusion was also followed by a shortening of the whole blood clotting time.

Heparin Concentrations Correlated To The Activated Whole Blood Clotting Time (Act) During Extracorporeal Circulation

1981 ◽  
Author(s):  
S Stenbjerg ◽  
E Berg ◽  
O K Albrechtsen
Keyword(s):  
Extracorporeal Circulation ◽  
Whole Blood ◽  
Blood Clotting ◽  
Heart Surgery ◽  
Open Heart Surgery ◽  
Open Heart ◽  
Excellent Correlation ◽  
Clotting Time ◽  
Automated Method ◽  
Blood Clotting Time

Heparin levels and ACT were followed during open heart surgery in lo patients. Heparin was assayed by an amidolytic method using substrate S-2222. ACT was determined with an automated method using celite and glass beads as activators of coagulation. Neither the hemodilution nor the depletion of platelets observed during extracorporeal circulation seemed to influence the ACT. An excellent correlation between the ACT and the actual heparin level was found in each patient with coefficients of correlation ranging from 0.73 – 0.97. A slightly better correlation was noticed for values of ACT below 600 seconds. It was concluded that the ACT is a valuable and reliable tool in control of heparinisation during open heart surgery.

Role of Trisodium Citrate in the Unclottability by Thrombin of Fibrinogen Metz

1975 ◽  
Author(s):  
C. Soria ◽  
J. Soria ◽  
M. Samama ◽  
E. Poirot ◽  
G. Kling
Keyword(s):  
Calcium Chloride ◽  
Whole Blood ◽  
Blood Clotting ◽  
Negative Charge ◽  
Trisodium Citrate ◽  
Thrombin Time ◽  
Clotting Time ◽  
Fibrin Formation ◽  
Blood Clotting Time

In a case of homozygous dysfibrinogenemia, the whole blood clotting time was moderately prolonged, while the thrombin clotting time was infinite, whatever dose or nature of thrombin used. Besides, the bleeding syndrome in this case was very weak.We observed also that only after trisodium citrate addition to purified fibrinogen, the abnormal fibrinogen became unclottable by thrombin even after addition of calcium chloride, since without trisodium citrate thrombin time was only prolonged.By immunoelectrophoresis and by isofocusing in the presence or in the absence of trisodium citrate, we therefore undertook to show that trisodium citrate reacts more strongly with the abnormal fibrinogen than with normal one. Thus, trisodium citrate conferring a negative charge to the pathological molecule, the abnormal fibrinogen became resistant to clotting with thrombin. Protamine sulfate, by positiving the charges of fibrinogen, partially corrects the defect in fibrin formation.

Sign in / Sign up

Export Citation Format

Share Document